The Clinical Role of miRNAs in the Development and Treatment of Glioblastoma
- PMID: 40141375
- PMCID: PMC11943032
- DOI: 10.3390/ijms26062723
The Clinical Role of miRNAs in the Development and Treatment of Glioblastoma
Abstract
Glioblastoma multiforme (GBM) is the most common brain tumor and one of the most aggressive, with a median overall survival (OS) of only 15-18 months. These characteristics make it necessary to identify new targets for the improvement of prognosis and better prediction of response to therapies currently available for GBM patients. One possible candidate target could be the evaluation of miRNAs. miRNAs are small non-coding RNAs that play important roles in post-transcriptional gene regulation. Due to their functions, miRNAs also control biological processes underlying the development of GBM and may be considered possible targets with a clinical role. This narrative review introduces the concept of miRNAs in GBM from a clinical and a molecular perspective and then addresses the specific miRNAs that are most described in the literature as relevant for the development, the prognosis, and the response to therapies for patients affected by GBM.
Keywords: GBM; TMZ; miRNAs; prognosis; survival; treatment.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures



Similar articles
-
MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics.Cancer Med. 2016 Aug;5(8):1917-46. doi: 10.1002/cam4.775. Epub 2016 Jun 10. Cancer Med. 2016. PMID: 27282910 Free PMC article. Review.
-
MicroRNAs in glioblastoma pathogenesis and therapy: A comprehensive review.Crit Rev Oncol Hematol. 2017 Dec;120:22-33. doi: 10.1016/j.critrevonc.2017.10.003. Epub 2017 Oct 7. Crit Rev Oncol Hematol. 2017. PMID: 29198335 Review.
-
Global MicroRNA Expression Profiling Identifies Unique MicroRNA Pattern of Radioresistant Glioblastoma Cells.Anticancer Res. 2017 Mar;37(3):1099-1104. doi: 10.21873/anticanres.11422. Anticancer Res. 2017. PMID: 28314270
-
Profiling of novel circulating microRNAs as a non-invasive biomarker in diagnosis and follow-up of high and low-grade gliomas.Clin Neurol Neurosurg. 2020 Mar;190:105652. doi: 10.1016/j.clineuro.2019.105652. Epub 2019 Dec 27. Clin Neurol Neurosurg. 2020. PMID: 31896490
-
Differential expression of MicroRNAs in patients with glioblastoma after concomitant chemoradiotherapy.OMICS. 2013 May;17(5):259-68. doi: 10.1089/omi.2012.0065. Epub 2013 Apr 15. OMICS. 2013. PMID: 23586679
Cited by
-
Inducer microRNAs in the glioma development: a concise review of mechanisms and insights into targeted therapy.J Egypt Natl Canc Inst. 2025 Aug 18;37(1):55. doi: 10.1186/s43046-025-00308-9. J Egypt Natl Canc Inst. 2025. PMID: 40820060 Review.
References
-
- Louis D.N., Perry A., Wesseling P., Brat D.J., Cree I.A., Figarella-Branger D., Hawkins C., Ng H.K., Pfister S.M., Reifenberger G., et al. The 2021 WHO Classification of Tumors of the Central Nervous System: A summary. Neuro-Oncology. 2021;23:1231–1251. doi: 10.1093/neuonc/noab106. - DOI - PMC - PubMed
-
- Wen P.Y., Weller M., Lee E.Q., Alexander B.M., Barnholtz-Sloan J.S., Barthel F.P., Batchelor T.T., Bindra R.S., Chang S.M., Chiocca E.A., et al. Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology. 2020;22:1073–1113. doi: 10.1093/neuonc/noaa106. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical